Search results
Author(s):
Marcel Weber
,
Jan-Malte Sinning
,
Christoph Hammerstingl
,
et al
Added:
3 years ago
Transcatheter aortic valve replacement (TAVR) has emerged as the treatment of choice among inoperable patients with symptomatic severe aortic stenosis and as a treatment alternative to surgical aortic valve replacement (SAVR) for high-risk surgical patients1–3. Subsequently, the number of patients undergoing TAVR worldwide is steadily increasing and the complications related to valve implantation…
View more
Impact on Implantation Depth
Author(s):
Verena Veulemans
,
Oliver Maier
,
Tobias Zeus
Added:
1 month ago
Article
Christoph Hammerstingl
Research Area(s) / Expertise:
Job title: Head of the department of Internal Medicine and Cardiology
Author
Author(s):
Ashok Seth
,
Vijay Kumar
,
Vivudh Pratap Singh
,
et al
Added:
11 months ago
Author(s):
Shu-I Lin
,
Mizuki Miura
,
Ana Paula Tagliari
,
et al
Added:
3 years ago
Transcatheter aortic valve implantation (TAVI) is now established as the standard treatment for symptomatic severe aortic stenosis (AS) in patients at high or prohibitive surgical risk, and the preferred treatment for those at intermediate risk.1
Based on recent trials in low-risk patients, the indications for TAVI are expanding towards the lower-risk classes, and the procedure has even been…
View more
Ghada Mikhail
Research Area(s) / Expertise:
Job title: Consultant cardiologist
Author
Foreword
Author(s):
Simon Kennon
Added:
3 years ago
Article
Author(s):
Alia Noorani
,
Vinayak Bapat
Added:
3 years ago
Transcatheter aortic valve implantation (TAVI) is an established alternative to surgical valve replacement in the management of calcified severe aortic stenosis in those with co-morbidities or adverse features (advanced age, impaired left ventricular function), or in those where open surgery may be associated with unfavourable technical features, such as previous sternotomy with a patent internal…
View more
Author(s):
James Gammie
Added:
2 years ago
In this short interview, Dr James Gammie (University of Maryland Medical Center, MD, US) discusses the findings from surgical trial assessing the benefit of concomitant tricuspid repair during mitral valve surgery. The trial, presented at AHA 2021, demonstrated that at 2 years, TA had no impact on MACCE, survival, or QOL.
Discussion Points
1. Reasoning for this Study
2. Study Design and…
View more
Author(s):
Lars Søndergaard
Added:
2 years ago
Prof Lars Søndergaard (Copenhagen University Hospital, Copenhagen, DK) discusses the 30-day outcomes from the Portico NG Study. The clinical study assessed the acute safety and effectiveness of the next-generation Portico™ NG Transcatheter Aortic Heart Valve.
Questions
1. Can you tell us more about the studied device and how it differs from the Portico™ TAVR?
2. What was the design, patient…
View more